Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: Case study with grapefruit juice and CYP3A4 drug substrates

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 576-584

  Ainslie, Garrett R ^a,d   Wolf, Kristina K ^c,e   Li, Yingxin ^c   Connolly, Elizabeth A ^c   Scarlett, Yolanda V ^b   Hull, J Heyward ^c   Paine, Mary F ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; CYTOCHROME P450 3A4; DRUG METABOLITE; FUROCOUMARIN; LOPERAMIDE; MORPHINE; N DESMETHYLLOPERAMIDE; UNCLASSIFIED DRUG; WATER; BIOLOGICAL MARKER; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; FEMALE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; MIOSIS; NORMAL HUMAN; OPEN STUDY; ORAL CLEARANCE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; BEVERAGE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; FORECASTING; GRAPEFRUIT; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; BEVERAGES; BIOMARKERS; CITRUS PARADISI; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; FOOD-DRUG INTERACTIONS; FORECASTING; HUMANS; LOPERAMIDE; MALE; MICROSOMES; MIDDLE AGED; PROSPECTIVE STUDIES; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 84908298020     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.216838     Document Type: Article

References (60)

1. Bailey DG, Dresser G, and Arnold JM (2013) Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ 185:309-316.
2. Brunton LL, Chabner BA, and Knollmann BC (2010) Appendix II, in Goodman & Gilman's: The Pharmalogical Basis of Therapeutics (Brunton L ed) McGraw Hill Medical, New York.
3. Damkier P, Hansen LL, and Brosen K (1999) Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 48:829-838.
4. Daniulaityte R, Carlson R, Falck R, Cameron D, Perera S, Chen L, and Sheth A (2013) "I just wanted to tell you that loperamide WILL WORK": a web-based study of extra-medical use of loperamide. Drug Alcohol Depend 130:241-244.
5. Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, and Roden DM (1997) Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 61:292-300.
6. De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, and Derendorf H (2006) Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 54:249-255.
7. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
8. Ducharme MP, Warbasse LH, and Edwards DJ (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57:485-491.
9. Eagling VA, Profit L, and Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543-552.
10. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
11. Fujioka Y, Kunze KL, and Isoherranen N (2012) Risk assessment of mechanism-based inactivation in drug-drug interactions. Drug Metab Dispos 40:1653-1657.
12. Galetin A, Gertz M, and Houston JB (2010) Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25:28-47.
13. Gertz M, Davis JD, Harrison A, Houston JB, and Galetin A (2008) Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9:785-795.
14. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
15. Goosen TC, Cillie D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, and Rheeders M, et al. (2004) Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 76:607-617.
16. Greenblatt DJ, Gan L, Harmatz JS, and Shader RI (2005) Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. Br J Clin Pharmacol 60:244-248.
17. Hanley MJ, Masse G, Harmatz JS, Court MH, and Greenblatt DJ (2012) Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. Clin Pharmacol Ther 92:651-657.
18. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, and Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 22:53-71.
19. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, and Heidemann H (1996) The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
20. Ito K, Suzuki H, Horie T, and Sugiyama Y (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22:1559-1577.
21. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, and Tucker G (2009) Population-based mechanistic prediction of oral drug absorption. AAPS J 11:225-237.
22. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, Hering U, Bulitta J, Schreiner P, Sörgel F, and Fuhr U (2002) Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 71:21-29.
23. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
24. Kharasch ED, Bedynek PS, Walker A, Whittington D, and Hoffer C (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 84:506-512.
25. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004a) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269.
26. Kharasch ED, Walker A, Hoffer C, and Sheffels P (2004b) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76:452-466.
27. Kim KA, Chung J, Jung DH, and Park JY (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60:575-581.
28. Lennernäs H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160.
29. Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, and Neuvonen PJ (1998) Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655-660.
30. Lilja JJ, Neuvonen M, and Neuvonen PJ (2004) Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58:56-60.
31. Liu C, Shang YF, Zhang XF, Zhang XG, Wang B, Wu Z, Liu XM, Yu L, Ma F, and Lv Y (2009) Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J Clin Pharmacol 65:881-885.
32. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, and Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553.
33. Lundahl J, Rega˚rdh CG, Edgar B, and Johnsson G (1997) Effects of grapefruit juice ingestion - pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 52:139-145.
34. Masica AL, Mayo G, and Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76:341-349.
35. Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo JP, and McCallister S (2005) Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 49:4903-4910.
36. National Center for Complementary and Alternative Medicine (2013) Dietary Supplement-Drug Interaction Expert Panel Meeting; 2013 Dec 4; Bethesda, MD.
37. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, and Backman JT (2006) Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463-472.
38. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
39. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
40. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
41. Odou P, Ferrari N, Barthélémy C, Brique S, Lhermitte M, Vincent A, Libersa C, and Robert H (2005) Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms. J Clin Pharm Ther 30:153-158.
42. Paine MF, Criss AB, and Watkins PB (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 32:1146-1153.
43. Paine MF, Criss AB, and Watkins PB (2005) Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 312:1151-1160.
44. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006b) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
45. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
46. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, and Watkins PB (2006a) A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097-1105.
47. Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, and Watkins PB (2008) Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 87:863-871.
48. Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, Derendorf H, Greenblatt DJ, and Browne K, Jr (2011) Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol 72:434-441.
49. Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, and Milstone A (2006) Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 62:485-491.
50. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, and Lötsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651-660.
51. Sklerov J, Levine B, Moore KA, Allan C, and Fowler D (2005) Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. J Anal Toxicol 29:750-754.
52. Streel B, Ceccato A, Klinkenberg R, and Hubert P (2005) Validation of a liquid chromatographic-tandem mass spectrometric method for the determination of loperamide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 814:263-273.
53. Sugimoto K, Araki N, Ohmori M, Harada K, Cui Y, Tsuruoka S, Kawaguchi A, and Fujimura A (2006) Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol 62:209-215.
54. Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, and Kimura M, et al. (2000) Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 67:201-214.
55. Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, and Bentz J (2004) Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93:2108-2123.
56. US Food and Drug Administration (2013) Draft Guidance: Bioanalytical Method Validation, US Food and Drug Administration, Rockville, MD.
57. Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, and Grime K, et al. (2014) Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin Pharmacol Ther 95:189-198.
58. Won CS, Oberlies NH, and Paine MF (2012) Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. Pharmacol Ther 136:186-201.
59. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
60. Yasui N, Kondo T, Furukori H, Kaneko S, Ohkubo T, Uno T, Osanai T, Sugawara K, and Otani K (2000) Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 150:185-190.